Previous close | 51.79 |
Open | 51.73 |
Bid | 51.00 x 100 |
Ask | 51.10 x 100 |
Day's range | 50.96 - 53.93 |
52-week range | 24.83 - 54.50 |
Volume | |
Avg. volume | 467,961 |
Market cap | 2.603B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time. Members of PROCEPT BioRobotics’ management team presenting include: Re
SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights Total revenue of approximately $43.6 million for the fourth quarter of 2023, an increase of 83% compared to the prior year periodU.S. system and rental revenue of $16.6 million for